These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 30335831)

  • 1. Subgroup identification in clinical trials via the predicted individual treatment effect.
    Ballarini NM; Rosenkranz GK; Jaki T; König F; Posch M
    PLoS One; 2018; 13(10):e0205971. PubMed ID: 30335831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplicity-adjusted semiparametric benefiting subgroup identification in clinical trials.
    Schnell PM; Müller P; Tang Q; Carlin BP
    Clin Trials; 2018 Feb; 15(1):75-86. PubMed ID: 29035083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Bayesian credible subgroups approach to identifying patient subgroups with positive treatment effects.
    Schnell PM; Tang Q; Offen WW; Carlin BP
    Biometrics; 2016 Dec; 72(4):1026-1036. PubMed ID: 27159131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian credible subgroup identification for treatment effectiveness in time-to-event data.
    Ngo D; Baumgartner R; Mt-Isa S; Feng D; Chen J; Schnell P
    PLoS One; 2020; 15(2):e0229336. PubMed ID: 32101562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Robust estimation of the expected survival probabilities from high-dimensional Cox models with biomarker-by-treatment interactions in randomized clinical trials.
    Ternès N; Rotolo F; Michiels S
    BMC Med Res Methodol; 2017 May; 17(1):83. PubMed ID: 28532387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confidence regions for treatment effects in subgroups in biomarker stratified designs.
    Wan F; Kunz CU; Jaki TF
    Biom J; 2019 Jan; 61(1):27-39. PubMed ID: 30474226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating optimal treatment regimes via subgroup identification in randomized control trials and observational studies.
    Fu H; Zhou J; Faries DE
    Stat Med; 2016 Aug; 35(19):3285-302. PubMed ID: 26892174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subgroup identification for treatment selection in biomarker adaptive design.
    Lu TP; Chen JJ
    BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Explaining heterogeneity of individual treatment causal effects by subgroup discovery: An observational case study in antibiotics treatment of acute rhino-sinusitis.
    Qi W; Abu-Hanna A; van Esch TEM; de Beurs D; Liu Y; Flinterman LE; Schut MC
    Artif Intell Med; 2021 Jun; 116():102080. PubMed ID: 34020753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to letter to the editor from Dr Rahman Shiri: The challenging topic of suicide across occupational groups.
    Niedhammer I; Milner A; Witt K; Klingelschmidt J; Khireddine-Medouni I; Alexopoulos EC; Toivanen S; Chastang JF; LaMontagne AD
    Scand J Work Environ Health; 2018 Jan; 44(1):108-110. PubMed ID: 29218357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DO CANCER CLINICAL TRIAL POPULATIONS TRULY REPRESENT CANCER PATIENTS? A COMPARISON OF OPEN CLINICAL TRIALS TO THE CANCER GENOME ATLAS.
    Geifman N; Butte AJ
    Pac Symp Biocomput; 2016; 21():309-20. PubMed ID: 26776196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of the average causal effect among subgroups defined by post-treatment variables.
    Matsuyama Y; Morita S
    Clin Trials; 2006; 3(1):1-9. PubMed ID: 16539085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexible shrinkage estimation of subgroup effects through Dirichlet process priors.
    Gamalo-Siebers M; Tiwari R; LaVange L
    J Biopharm Stat; 2016; 26(6):1040-1055. PubMed ID: 27548701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of predictive signatures for treatment selection in precision medicine with survival outcomes.
    Chen YC; Lee UJ; Tsai CA; Chen JJ
    Pharm Stat; 2018 Mar; 17(2):105-116. PubMed ID: 29297979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploratory subgroup analysis in clinical trials by model selection.
    Rosenkranz GK
    Biom J; 2016 Sep; 58(5):1217-28. PubMed ID: 27230820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modeling Clinical Outcomes in Prostate Cancer: Application and Validation of the Discrete Event Simulation Approach.
    Pan F; Reifsnider O; Zheng Y; Proskorovsky I; Li T; He J; Sorensen SV
    Value Health; 2018 Apr; 21(4):416-422. PubMed ID: 29680098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
    Seidenfeld J; Samson DJ; Aronson N; Albertson PC; Bayoumi AM; Bennett C; Brown A; Garber A; Gere M; Hasselblad V; Wilt T; Ziegler K
    Evid Rep Technol Assess (Summ); 1999 May; (4):i-x, 1-246, I1-36, passim. PubMed ID: 11098244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.
    Lipkovich I; Dmitrienko A; B R
    Stat Med; 2017 Jan; 36(1):136-196. PubMed ID: 27488683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment effect heterogeneity for univariate subgroups in clinical trials: Shrinkage, standardization, or else.
    Varadhan R; Wang SJ
    Biom J; 2016 Jan; 58(1):133-53. PubMed ID: 26485117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.